Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
Neuromuscular Disorders (2022) Vol. 32, Iss. 4, pp. 271-283
Open Access | Times Cited: 23

Showing 23 citing articles:

Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
Jerry R. Mendell, Perry B. Shieh, Craig M. McDonald, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 41
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)
Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald, et al.
Annals of Neurology (2023) Vol. 94, Iss. 5, pp. 955-968
Open Access | Times Cited: 38
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
Neurology (2023) Vol. 100, Iss. 15
Open Access | Times Cited: 24
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective
Rui Zhu, Bianca Vora, Sujatha Menon, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 751-767
Open Access | Times Cited: 20
First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD
Laurent Servais, Damien Eggenspieler, Margaux Poleur, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2391-2392
Closed Access | Times Cited: 20
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
Galina Filonova, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 2, pp. 133-143
Open Access | Times Cited: 17
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304984-e0304984
Open Access | Times Cited: 5
Report on the 6th Ottawa International Conference on Neuromuscular Disease & Biology – September 7–9, 2023, Ottawa, Canada
Jodi Warman‐Chardon, Bernard J. Jasmin, Rashmi Kothary, et al.
Journal of Neuromuscular Diseases (2025) Vol. 12, Iss. 1
Closed Access
Visualizing ambulatory performance by age and rates of decline among patients with Duchenne muscular dystrophy
Anna Mayhew, James Signorovitch, Michaela Johnson, et al.
Journal of Neuromuscular Diseases (2025)
Closed Access
Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy
Hiroyuki Awano, Yoshinori Nambu, Chieko Itoh, et al.
Muscle & Nerve (2024) Vol. 69, Iss. 5, pp. 604-612
Open Access | Times Cited: 2
Outcome Measures in Duchenne Muscular Dystrophy
Silvia Benemei, Francesca Gatto, Luca Boni, et al.
Acta Neurologica Belgica (2024)
Open Access | Times Cited: 2
Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021
Lei Zhao, Yiyun Shi, Chaoping Hu, et al.
Orphanet Journal of Rare Diseases (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition
Hannah J. Gleneadie, Beatriz Fernandez-Ruiz, Alessandro Sardini, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes
Katherine Gooch, Ivana Audhya, Kristen Ricchetti-Masterson, et al.
Advances in Therapy (2024) Vol. 41, Iss. 9, pp. 3615-3632
Open Access | Times Cited: 1
Antisense oligonucleotides in rare neurogenetic disorders
Hui Jin Shin, Ara Ko, Jiyoung Oh, et al.
Journal of Genetic Medicine (2024) Vol. 21, Iss. 2, pp. 41-50
Open Access | Times Cited: 1
269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy – What have we learned? 9–11 December 2022, Hoofddorp, The Netherlands
Karin J. Naarding, Georgia Stimpson, Susan J. Ward, et al.
Neuromuscular Disorders (2023) Vol. 33, Iss. 11, pp. 897-910
Closed Access | Times Cited: 3
Dynamic Enrichment of Bayesian Small-Sample, Sequential, Multiple Assignment Randomized Trial Design Using Natural History Data: A Case Study from Duchenne Muscular Dystrophy
Sidi Wang, Kelley M. Kidwell, Satrajit Roychoudhury
Biometrics (2023) Vol. 79, Iss. 4, pp. 3612-3623
Open Access | Times Cited: 2
Appendicular lean mass index and motor function in ambulatory patients with Duchenne muscular dystrophy
Michael Kiefer, Elise L. Townsend, C. Goncalves, et al.
Muscle & Nerve (2024) Vol. 70, Iss. 2, pp. 226-231
Open Access
The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data
Nienke M. van de Velde, Yvonne D. Krom, J. Bongers, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 5, pp. 1095-1109
Open Access
Characterization of patients with Duchenne muscular dystrophy across previously developed health states
Francesco Muntoni, Nathalie Goemans, N. Posner, et al.
PLoS ONE (2024) Vol. 19, Iss. 10, pp. e0307118-e0307118
Open Access
Tamoxifen in children with Duchenne muscular dystrophy
Laurent Servais
The Lancet Neurology (2023) Vol. 22, Iss. 10, pp. 872-873
Closed Access
Becker Muscular Dystrophy: Could Altering the Natural History of Decline Help Tackle Unmet Medical Need?
Amanda Barrell
European Medical Journal (2023), pp. 33-40
Open Access
Natural history of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy: a retrospective study at a single referral center in Japan
Hiroyuki Awano, Yoshinori Nambu, Chieko Ito, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top